Risks and Opportunities of AI in Clinical Drug Development
May 18, 2020, Columbia University, New York City
Joseph D. Jamail Lecture Hall at Pulitzer Hall, Columbia University, 2950 Broadway, New York, 10027
Where will the AI revolution take pharmaceutical science?
Conference Co-Chairs: Demissie Alemayehu, Pfizer Inc. and David Madigan, Columbia University
The Pfizer/ASA/Columbia University Symposium on Risks and Opportunities of AI in Clinical Drug Development is an event jointly sponsored by Pfizer Inc., the American Statistical Association (ASA), and the Statistics Department and Data Science Institute at Columbia University.
Our world increasingly relies on data and computing to create knowledge, to make critical decisions, and to better predict the future. Data science has emerged to support these data-driven activities by integrating and developing ideas, concepts, and tools from computer science, engineering, information science, statistics, and domain fields. Data science now drives fields as diverse as biology, astronomy, material science, political science, and medicine—not to mention vast tracts of the global economy, key government activities, and quotidian social and societal functions.
The pharmaceutical enterprise has been slower to respond, especially to the rapid developments in AI, but tectonic shifts are underway in approaches to the discovery, development, evaluation, registration, monitoring, and marketing of medicines for the benefit of patients and the health of the community.